| Name | Description | Data sources | Responsible organisation(s) | Measure methodology last updated |
|---|---|---|---|---|
| People with diabetes regularly receiving any hypoglycaemic medication in the relevant year | This indicator shows the number and percent of people with diabetes receiving any hypoglycaemic medication regularly. Regular use was defined as hypoglycaemic medication dispensed in three or more quarters in a year |
Pharmaceutical Collection (PHARMS), Primary Health Organisation (PHO) Enrolment Collection, Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| People with diabetes regularly receiving sulfonylureas | This indicator shows the number and percent of people with diabetes receiving sulfonylureas (glibenclamide, gliclazide and glipizide) regularly. Regular use was defined as sulfonylureas dispensed in three or more quarters in a year. |
Pharmaceutical Collection (PHARMS), Primary Health Organisation (PHO) Enrolment Collection, Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| People with diabetes regularly receiving dulaglutide | This indicator shows the number and percent of people with diabetes receiving dulaglutide regularly. Regular use was defined as dulaglutide dispensed in three or more quarters in a year. |
Pharmaceutical Collection (PHARMS), Primary Health Organisation (PHO) Enrolment Collection, Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| People with diabetes regularly receiving empagliflozin | This indicator shows the number and percent of people with diabetes receiving empagliflozin regularly. Regular use was defined as empagliflozin dispensed in three or more quarters in a year. |
Pharmaceutical Collection (PHARMS), Primary Health Organisation (PHO) Enrolment Collection, Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| People with diabetes regularly receiving vildagliptin | This indicator shows the number and percent of people with diabetes receiving vildagliptin regularly. Regular use was defined as vildagliptin dispensed in three or more quarters in a year. |
Pharmaceutical Collection (PHARMS), Virtual Diabetes Register (VDR) | Health Quality & Safety Commission | Te Tāhū Hauora | June 2024 |
| People aged 12–44 dispensed a combined budesonide + formoterol inhaler | This indicator shows the number and percent of people aged 12-44 years who were regularly dispensed SMART Formoterol/Budesonide therapy. Regular dispensing was defined as dispensing in two or more quarters in the year. This indicator measures uptake of this inhaler, relative to other asthma inhalers. Specifically, of all people who were dispensed any asthma inhaler (SABA, LABA, ICS or LABA/ICS combination), what percentage were dispensed a combined budesonide + formoterol inhaler. |
Pharmaceutical Collection (PHARMS), PHO Enrolment Collection | Health Quality & Safety Commission | Te Tāhū Hauora | September 2025 |
| Dispensed a urate-lowering therapy | This measure shows the percentage of people with identified gout who received urate-lowering therapy at least once in a year. Long-term urate-lowering therapy is used to prevent gout flares and prevent tophus formation, bony erosions and permanent disability in people with gout. Many studies have demonstrated underutilisation of urate-lowering therapy continuously and long term. | National Minimum Dataset, Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ | Health Quality & Safety Commission | Te Tāhū Hauora | |
| Available places in approved classes | This is a measure of the total number of places offered to people in community group strength and balance classes. ACC-approved community strength and balance classes can help to prevent falls and reduce fall-related harm. This measure identifies whether there are sufficient opportunities for older people to participate in classes. The goal is to maintain enough class places across the country for the at-risk population to access and lower their falls risk. | Lead indicators - ACC | Health Quality & Safety Commission | Te Tāhū Hauora | |
| Reach | This is a measure of how many new unique people have begun participating in community group strength and balance classes. Strength and balance classes in the community and home can help to prevent falls and reduce fall-related harm. | Lead indicators - ACC | Health Quality & Safety Commission | Te Tāhū Hauora | |
| Walking ability at 120 days | This is a measure of the percentage of hip fracture patients who returned to their pre-fracture mobility at 120 days after admission. | Australian & New Zealand Hip Fracture Registry | Health Quality & Safety Commission | Te Tāhū Hauora |